Buoyed by semaglutide success, Novo Nordisk uncorks plans for $2.58B manufacturing expansion in Denmark
Novo Nordisk scored a pair of double wins the last couple years with the approval of two different forms of semaglutide, the company’s newest blockbuster product line. Now, Novo is setting aside a serious pile of cash to take its manufacturing ops into the future as the company looks to level up.
Novo will invest roughly $2.58 billion (DKK 17 billion) to greatly expand its manufacturing footprint at its central hub in Kalundborg, Denmark, with three new facilities and the expansion of a fourth on the way, the company said this week.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,500+ biopharma pros reading Endpoints daily — and it's free.